Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC Sept 2021 | Horizon scanning in interventional pulmonology: intratumoral therapy & tumor ablation

Christopher Manley, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses some of the exciting advances in interventional pulmonology on the horizon that could have a positive impact on lung cancer care. The direct injection of anti-tumor therapy into lung lesions could allow the use of lower therapeutic doses compared to current systemic therapies and could therefore reduce treatment-related side effects. Dr Manley also explains that tumor ablation could be a promising option for patients with lung cancer that are too fragile to undergo surgery or radiation and could offer a potential treatment for patients with metastatic disease. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.


Dr Manley serves as a consultant for Johnson and Johnson and Auris Health. He has received research grant funding from Mauna Kea and Johnson and Johnson.